| Print
AtaiBeckley Inc (ATAI)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Atai Beckley NV Third Quarter Earnings Results for 2026 | 2026-11-12T00:00:00 |
| ATAI Life Sciences NV Second Quarter Earnings Results for 2026 | 2026-08-14T00:00:00 |
| ATAI Life Sciences NV Annual General Meeting for 2026 | 2026-05-15T18:00:00 |
| ATAI Life Sciences NV First Quarter Earnings Results for 2026 | 2026-05-14T00:00:00 |
| ATAI Life Sciences NV Annual Report for 2025 | 2026-03-17T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Jefferies Global Healthcare Conference | 2025-11-20T06:30:00 |
| Atai Beckley NV Third Quarter Earnings Results for 2025 | 2025-11-12T00:00:00 |
| BPL-003 Phase 2b Open-Label Extension Data | 2025-11-10T08:00:00 |
| TD Cowen 5(th) Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Su | 2025-09-17T10:00:00 |
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-08T11:30:00 |
| Cantor Global Healthcare Conference 2025 | 2025-09-05T08:35:00 |
| ATAI Life Sciences NV Second Quarter Earnings Results for 2025 | 2025-08-14T00:00:00 |
| H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | 2025-06-17T07:00:00 |
| Jefferies Global Healthcare Conference | 2025-06-05T09:55:00 |
| ATAI Life Sciences NV Annual General Meeting for 2025 | 2025-05-15T18:00:00 |
| ATAI Life Sciences NV First Quarter Earnings Results for 2025 | 2025-05-14T00:00:00 |
| ATAI Life Sciences NV Annual Report for 2024 | 2025-03-17T00:00:00 |
| TD Cowen 45th Annual Health Care Conference | 2025-03-03T11:50:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.